<!DOCTYPE html>
<html>
  <head> <!--Head is where information/links are stored-->
    <link rel="stylesheet" href="XolairStyle.css"> <!--Links CSS code-->
    <script src="Xolair.js"></script> <!--Links JavaScript-->
  </head>

  <body> <!--Body is where the main code is stored-->
    <!--Top menu bar links-->

    <div>
        <img class="Xo" src="https://seeklogo.com/images/N/novartis-xolair-omalizumab-logo-0D939AD4DF-seeklogo.com.png">
        <br><h1 class="Xotext">Treatment for Asthma</h1><br><br>
    </div>
    <ul>
        <div class="menu">
            <li><a href="index.html">Overview</a></li>
            <li><a href="XoAsthma.html">Asthma</a></li>
            <li><a href="XoBioChar.html">Biologic Characteristics</a></li>
            <li><a href="XoManufacturing.html">Manufacturing</a></li>
            <li><a href="XoReferences.html">Resources</a></li>
            </div>
      </ul>

      <h3>References</h3>
      <ol id="sources">
              <li><a class="link" href="https://clinicaltrials.gov/ct2/show/NCT00314574?term=Xolair&recrs=e&rslt=With&type=Intr&cond=Asthma&draw=2&rank=1">A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA) - Full Text View. (n.d.).</a></li>
              <li><a class="link" href="http://article.sapub.org/10.5923.j.als.20140403.03.html">Agadagba, S. K. (n.d.). Therapeutic Antibody Case Study: Humanized Xolair.</a></li>
              <li><a class="link" href="https://www.mayoclinic.org/diseases-conditions/asthma/symptoms-causes/syc-20369653">Asthma. (2020, August 11).</a></li>
              <li><a class="link" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-asthma-drug-xolair-omalizumab-including">Center for Drug Evaluation and Research. (n.d.). FDA approves label changes for asthma drug Xolair.</a></li>
              <li><a class="link" href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=600&showFR=1&subpartNode=21:7.0.1.1.1.2">CFR - Code of Federal Regulations Title 21. (n.d.).</a></li>
              <li><a class="link" href="https://www.gene.com/media/press-releases/14904/2021-04-12/fda-approves-xolair-omalizumab-prefilled">Genentech: Press Releases: Monday, Apr 12, 2021. (n.d.).</a></li>
              <li><a class="link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873975/">Pennington, L. F., Tarchevskaya, S., Brigger, D., Sathiyamoorthy, K., Graham, M. T., Nadeau, K. C., . . . Jardetzky, T. S. (2016, May 19). Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.</a></li>
              <li><a class="link" href="https://labtestsonline.org/tests/total-ige">Total IgE. (n.d.).</a></li>
              <li><a class="link" href="https://www.genengnews.com/news/first-mab-produced-via-fully-continuous-biomanufacturing/">Vuksanaj, K. (2019, October 04). First mAb Produced via Fully Continuous Biomanufacturing.</a></li>
              <li><a class="link" href="https://www.xolairhcp.com/allergic-asthma.html">When It's Allergic Asthma, Think XOLAIR. The Only Anti-IgE Therapy Approved Since 2003 for Allergic Asthma Treatment. (n.d.).</a></li>
      </ol>

      <br><br><br>
      <p>What I found the most interesting while researching this biologic was that doctors still are uncertain what is the root cause of asthma. It is pretty unbeleivable that scientitsts know enough about asthma to effectivly manage symptoms with many different treatment options but still do not know why some people have asthma and others do not.</p>

  </body>
</html>